Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Price Is Right: Amgen Defends Repatha At $9,669 Against More Critics

23 Aug 2017

• By Emily Hayes

Cholesterol plaque in artery

Related Content

Amgen's Repatha Contract With Harvard Pilgrim Includes A Full Refund

03 May 2017

Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?

18 Mar 2017

Amgen's Ofman On Value-Based Contracts And Reimbursement Challenges

07 Jul 2017

Amgen Beats Consensus, Raises Earnings Guidance, But Is It Sustainable?

26 Jul 2017

Amgen Faces New ICER Roadblock To Repatha Reimbursement

15 Jun 2017

Related Companies

Amgen, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Merck & Co., Inc.

Additional Topics

Pricing Strategies Cost Effectiveness Reimbursement Market Access Commercial Cardiovascular BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.